Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Viking Therapeutics, Inc.

Biotech R&D: ADMA vs. Viking - A Decade of Innovation

__timestampADMA Biologics, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014951701422223073
Thursday, January 1, 201570159466966842
Friday, January 1, 201676882389000499
Sunday, January 1, 2017622958713741186
Monday, January 1, 2018392612019040000
Tuesday, January 1, 2019234384823559000
Wednesday, January 1, 2020590701331931000
Friday, January 1, 2021364606044981000
Saturday, January 1, 2022361376454234000
Sunday, January 1, 2023330000063806000
Loading chart...

Igniting the spark of knowledge

Innovation in Biotech: A Comparative Analysis

In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, ADMA Biologics, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.

ADMA Biologics, Inc.

From 2014 to 2023, ADMA Biologics, Inc. has shown a steady decline in R&D spending, with a notable 65% decrease from its peak in 2014. This trend suggests a strategic shift or potential resource reallocation within the company.

Viking Therapeutics, Inc.

Conversely, Viking Therapeutics, Inc. has consistently increased its R&D budget, culminating in a nearly 190% rise by 2023. This robust investment underscores their aggressive pursuit of innovation and market leadership.

As the biotech landscape continues to evolve, these spending patterns offer valuable insights into each company's strategic priorities and future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025